Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594502 · ClinicalTrials.gov registry record
Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 139
- Enrollment target
NCT01594502 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 139 participants.
The verdict
NCT01594502 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 139 participants
- Enrollment target
Study Summary
The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemoprevention as well as the risk of prostate cancer among men with negative biopsies.
Interventions
- DRUG Placebo
- DRUG Dutasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01594502
The ClinicalTrials.gov registry entry for NCT01594502 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01594502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01594502 about?
NCT01594502 is a clinical study titled "Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies". The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemo...
What is the current status of trial NCT01594502?
This trial is currently completed. The enrollment target is 139 participants. The study started on 2011-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01594502?
The interventions under investigation include: Placebo (DRUG), Dutasteride (DRUG).
Who is sponsoring clinical trial NCT01594502?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.